Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gene therapy: new developments].

L Mohr1, M Geissler

  • 1Medizinische Universitätsklinik II, Freiburg. mohrl@sun11.ukl.uni-freiburg.de

Praxis
|February 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

ESMO open·2024
Same author

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.

ESMO open·2023
Same author

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

The B-type natriuretic peptide of the Congo and Timneh grey parrot.

Veterinary research communications·2021
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Gene therapy uses vectors to deliver therapeutic genes for genetic and acquired diseases. Viral vectors offer efficient gene transfer, with ongoing research focused on improving safety and efficacy for various applications.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Context:

  • Gene therapy aims to treat diseases by transferring therapeutic genes into target cells.
  • Both genetic and acquired diseases, including cancers, are potential targets for gene therapy.
  • Safe and efficient gene transfer is crucial for gene therapy's success.

Purpose:

  • To review current gene therapy vector systems, including nonviral and viral options.
  • To discuss the advantages and limitations of different vector types for gene delivery.
  • To highlight novel developments in viral vector technology for enhanced therapeutic outcomes.

Summary:

  • Nonviral vectors are less efficient but safer than viral vectors, with potential for improvement by incorporating viral functions.

Related Experiment Videos

  • Viral vectors, including retroviruses, adeno-associated viruses, and lentiviruses, enable permanent gene expression.
  • Adenoviral vectors provide transient gene expression, ideal for cancer treatment, while novel oncolytic viruses offer targeted tumor cell lysis.

    • Impact:

    • Advancements in vector design are reducing immunogenicity and increasing gene-carrying capacity.
    • Improved vector production methods are essential for clinical translation.
    • Next-generation viral vectors, including oncolytic viruses, promise enhanced tumor-specific toxicity and therapeutic gene delivery.